Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Thrombopoietin Receptor Agonists [MoA]

Known as: Thrombopoietin Receptor Agonists 
National Institutes of Health

Related topics

Related topics

3 relations
eltrombopageltrombopag 25 MG Oral Tabletromiplostim

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Thrombopoietin receptor agonists and risk of portal vein thrombosis in patients with liver disease and thrombocytopenia: A meta-analysis.
  • L. Loffredo, F. Violi
  • Digestive and liver disease : official journal of…
  • 2019
    • Corpus ID: 49613989
BACKGROUND Treatment of thrombocytopenia with thrombopoietin receptor agonists (TPORAs) seems to be associated with portal vein… Expand
Review
2017
Review
2017
Beyond immune thrombocytopenia: the evolving role of thrombopoietin receptor agonists
Since its discovery, the thrombopoietin (TPO) pathway has been an important pharmaceutical target for the treatment of… Expand
  • table 2
  • table 3
Review
2016
Review
2016
Advances in Diagnosis and Treatments for Immune Thrombocytopenia
  • S. Nomura
  • Clinical medicine insights. Blood disorders
  • 2016
    • Corpus ID: 14735203
Immune thrombocytopenia (ITP) is an acquired hemorrhagic condition characterized by the accelerated clearance of platelets caused… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
2016
2016
Real-life management of primary immune thrombocytopenia (ITP) in adult patients and adherence to practice guidelines
Very few data exist on the management of adult patients diagnosed with primary immune thrombocytopenia (ITP). The objectives of… Expand
  • table 1
  • table 3
  • table 4
  • table 5
2015
2015
Outpatient Management of Patients with Immune Thrombocytopenia (ITP) by Hematologists 1995-2014
Background: The aim of this study was to evaluate the treatment reality for outpatients with immune thrombocytopenia (ITP… Expand
  • table 1
  • figure 1
Review
2015
Review
2015
Use of Thrombopoietin Receptor Agonists in Childhood Immune Thrombocytopenia
Most children with immune thrombocytopenia (ITP) will have spontaneous remission regardless of therapy, while about 20% will go… Expand
  • figure 1
  • table 1
Highly Cited
2013
Highly Cited
2013
Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists
Thrombopoietin receptor agonists (TRAs) are effective treatments for immune thrombocytopenia (ITP). However, continuous therapy… Expand
Highly Cited
2013
Highly Cited
2013
Long‐term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials
Thrombopoietin receptor agonists (TPOra) are the only treatments for immune thrombocytopenia (ITP) for which evidence of efficacy… Expand
Review
2013
Review
2013
Immune thrombocytopenia – what are the new treatment options?
Introduction: Primary immune thrombocytopenia (ITP) is a minor disease for many patients; however, the natural history is… Expand
2011
2011
Platelet Kinetics in Idiopathic Thrombocytopenic Purpura Patients Treated with Thrombopoietin Receptor Agonists
Aim: Thrombopoietin receptor agonists (Tpo increase platelet counts in the majority of chronic autoimmune thrombocytopenia… Expand
  • table 1
  • table 2
  • figure 2
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE